Published in Clin Chem on August 21, 2008
Pancreatic cancer. Lancet (2004) 11.63
MicroRNA-10b expression correlates with response to neoadjuvant therapy and survival in pancreatic ductal adenocarcinoma. Clin Cancer Res (2011) 2.95
MicroRNA array analysis finds elevated serum miR-1290 accurately distinguishes patients with low-stage pancreatic cancer from healthy and disease controls. Clin Cancer Res (2013) 2.71
miRNA biomarkers in cyst fluid augment the diagnosis and management of pancreatic cysts. Clin Cancer Res (2012) 2.10
A pilot study to develop a diagnostic test for pancreatic ductal adenocarcinoma based on differential expression of select miRNA in plasma and bile. Am J Gastroenterol (2014) 2.02
MicroRNA alterations of pancreatic intraepithelial neoplasias. Clin Cancer Res (2011) 1.97
MicroRNA profiling of diagnostic needle aspirates from patients with pancreatic cancer. Br J Cancer (2012) 1.90
Restitution of tumor suppressor microRNAs using a systemic nanovector inhibits pancreatic cancer growth in mice. Mol Cancer Ther (2011) 1.76
MicroRNA-196: critical roles and clinical applications in development and cancer. J Cell Mol Med (2011) 1.59
Current status of molecular markers for early detection of sporadic pancreatic cancer. Biochim Biophys Acta (2010) 1.58
Metastamirs: a stepping stone towards improved cancer management. Nat Rev Clin Oncol (2010) 1.58
Mirna expression profiles identify drivers in colorectal and pancreatic cancers. PLoS One (2012) 1.47
Contribution of microRNA to pathological fibrosis in cardio-renal syndrome: impact of uremic toxins. Physiol Rep (2015) 1.40
Retracted Reanalysis of the gene expression profile in chronic pancreatitis via bioinformatics methods. Eur J Med Res (2014) 1.39
Detection of differentially expressed microRNAs in serum of pancreatic ductal adenocarcinoma patients: miR-196a could be a potential marker for poor prognosis. Dig Dis Sci (2010) 1.35
MicroRNAs targeting oncogenes are down-regulated in pancreatic malignant transformation from benign tumors. PLoS One (2012) 1.27
Elevated microRNA miR-21 levels in pancreatic cyst fluid are predictive of mucinous precursor lesions of ductal adenocarcinoma. Pancreatology (2011) 1.22
microRNA-10b enhances pancreatic cancer cell invasion by suppressing TIP30 expression and promoting EGF and TGF-β actions. Oncogene (2013) 1.18
Prognostic microRNAs in cancer tissue from patients operated for pancreatic cancer--five microRNAs in a prognostic index. World J Surg (2012) 1.14
Advances in biomarker research for pancreatic cancer. Curr Pharm Des (2012) 1.05
Changes of microRNAs-192, 196a and 203 correlate with Barrett's esophagus diagnosis and its progression compared to normal healthy individuals. Diagn Pathol (2011) 1.04
MicroRNA in pancreatic cancer: pathological, diagnostic and therapeutic implications. Cancer Lett (2009) 1.01
MicroRNA-196a and -196b as Potential Biomarkers for the Early Detection of Familial Pancreatic Cancer. Transl Oncol (2014) 1.00
Clinical implications of miRNAs in the pathogenesis, diagnosis and therapy of pancreatic cancer. Adv Drug Deliv Rev (2014) 1.00
MicroRNAs as emerging biomarkers and therapeutic targets for pancreatic cancer. World J Gastroenterol (2014) 0.98
MicroRNA expression aids the preoperative diagnosis of pancreatic ductal adenocarcinoma. Pancreas (2012) 0.98
MicroRNAs in pancreatic cancer metabolism. Nat Rev Gastroenterol Hepatol (2012) 0.97
MicroRNAs in pancreatic ductal adenocarcinoma. World J Gastroenterol (2011) 0.93
Utilization of ancillary studies in the cytologic diagnosis of biliary and pancreatic lesions: the Papanicolaou Society of Cytopathology guidelines for pancreatobiliary cytology. Diagn Cytopathol (2014) 0.92
Aberrant MicroRNAs in Pancreatic Cancer: Researches and Clinical Implications. Gastroenterol Res Pract (2014) 0.91
Roles and mechanisms of microRNAs in pancreatic cancer. World J Surg (2011) 0.90
Improvement of prostate cancer detection by integrating the PSA test with miRNA expression profiling. Cancer Invest (2011) 0.89
Improvement of long-term outcomes in pancreatic cancer and its associated factors within the gemcitabine era: a collaborative retrospective multicenter clinical review of 1,082 patients. BMC Gastroenterol (2013) 0.89
MiR-21, miR-34a, miR-198 and miR-217 as diagnostic and prognostic biomarkers for chronic pancreatitis and pancreatic ductal adenocarcinoma. Diagn Pathol (2015) 0.88
Cyst fluid biomarkers for intraductal papillary mucinous neoplasms of the pancreas: a critical review from the international expert meeting on pancreatic branch-duct-intraductal papillary mucinous neoplasms. J Am Coll Surg (2014) 0.88
Pancreatic cancer stromal biology and therapy. Genes Dis (2015) 0.87
Role of endoscopic ultrasound in the molecular diagnosis of pancreatic cancer. World J Gastroenterol (2014) 0.86
Changes in microRNA (miRNA) expression during pancreatic cancer development and progression in a genetically engineered KrasG12D;Pdx1-Cre mouse (KC) model. Oncotarget (2015) 0.84
miR-216 and miR-217 expression is reduced in transgenic mouse models of pancreatic adenocarcinoma, knockout of miR-216/miR-217 host gene is embryonic lethal. Funct Integr Genomics (2016) 0.83
MicroRNAs in Pancreatic Cancer: Involvement in Carcinogenesis and Potential Use for Diagnosis and Prognosis. Gastroenterol Res Pract (2015) 0.82
Alterations of MicroRNAs in Solid Cancers and Their Prognostic Value. Cancers (Basel) (2010) 0.82
Utilization of ancillary studies in the cytologic diagnosis of biliary and pancreatic lesions: The Papanicolaou Society of Cytopathology Guidelines. Cytojournal (2014) 0.82
Targeting miRNAs for pancreatic cancer therapy. Curr Pharm Des (2014) 0.81
Emerging roles of microRNAs in pancreatic cancer diagnosis, therapy and prognosis (Review). Int J Oncol (2015) 0.81
Targeted destruction of the orchestration of the pancreatic stroma and tumor cells in pancreatic cancer cases: molecular basis for therapeutic implications. Cytokine Growth Factor Rev (2012) 0.81
Aberrant epigenetic grooming of miRNAs in pancreatic cancer: a systems biology perspective. Epigenomics (2011) 0.80
Plasma microRNA panels to diagnose pancreatic cancer: Results from a multicenter study. Oncotarget (2016) 0.80
Highly specific plasmonic biosensors for ultrasensitive microRNA detection in plasma from pancreatic cancer patients. Nano Lett (2014) 0.80
The Role of microRNAs in the Diagnosis and Treatment of Pancreatic Adenocarcinoma. J Clin Med (2016) 0.80
MicroRNA Expression in Selected Carcinomas of the Gastrointestinal Tract. Patholog Res Int (2011) 0.80
Reliable gene expression measurements from fine needle aspirates of pancreatic tumors: effect of amplicon length and quality assessment. J Mol Diagn (2010) 0.79
MicroRNAs for Detection of Pancreatic Neoplasia: Biomarker Discovery by Next-generation Sequencing and Validation in 2 Independent Cohorts. Ann Surg (2017) 0.78
MicroRNA-183-5p promotes the proliferation, invasion and metastasis of human pancreatic adenocarcinoma cells. Oncol Lett (2015) 0.77
Small nucleolar RNA U91 is a new internal control for accurate microRNAs quantification in pancreatic cancer. BMC Cancer (2015) 0.77
Prospective validation of microRNA signatures for detecting pancreatic malignant transformation in endoscopic-ultrasound guided fine-needle aspiration biopsies. Oncotarget (2016) 0.76
miRNAs As Diagnostic and Prognostic Biomarkers in Pancreatic Ductal Adenocarcinoma and Its Precursor Lesions: A Review. Biomark Insights (2015) 0.76
The miRacle in Pancreatic Cancer by miRNAs: Tiny Angels or Devils in Disease Progression. Int J Mol Sci (2016) 0.76
Profilings of MicroRNAs in the Liver of Common Carp (Cyprinus carpio) Infected with Flavobacterium columnare. Int J Mol Sci (2016) 0.76
Plasma microRNAs as biomarkers of pancreatic cancer risk in a prospective cohort study. Int J Cancer (2017) 0.75
High Throughput Sequencing of Extracellular RNA from Human Plasma. PLoS One (2017) 0.75
Tissue MicroRNA profiles as diagnostic and prognostic biomarkers in patients with resectable pancreatic ductal adenocarcinoma and periampullary cancers. Biomark Res (2017) 0.75
A microRNA signature in circulating exosomes is superior to exosomal glypican-1 levels for diagnosing pancreatic cancer. Cancer Lett (2017) 0.75
Molecular diagnostics of pancreatic cysts. Langenbecks Arch Surg (2013) 0.75
MicroRNA expression levels as diagnostic biomarkers for intraductal papillary mucinous neoplasm. Oncotarget (2017) 0.75
Identifying the miRNA signature associated with survival time in patients with lung adenocarcinoma using miRNA expression profiles. Sci Rep (2017) 0.75
Cancer statistics, 2007. CA Cancer J Clin (2007) 53.49
MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA (2007) 9.97
Systematic analysis of microRNA expression of RNA extracted from fresh frozen and formalin-fixed paraffin-embedded samples. RNA (2007) 5.35
MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene (2007) 4.46
Stability of endogenous and added RNA in blood specimens, serum, and plasma. Clin Chem (2002) 3.72
Quantitative mRNA expression analysis from formalin-fixed, paraffin-embedded tissues using 5' nuclease quantitative reverse transcription-polymerase chain reaction. J Mol Diagn (2000) 3.59
Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies. Cancer Res (2003) 3.23
Evaluation and validation of total RNA extraction methods for microRNA expression analyses in formalin-fixed, paraffin-embedded tissues. J Mol Diagn (2008) 2.50
Low correspondence between K-ras mutations in pancreatic cancer tissue and detection of K-ras mutations in circulating DNA. Pancreas (2006) 2.31
The clinical utility of endoscopic ultrasound-guided fine-needle aspiration in the diagnosis and staging of pancreatic carcinoma. Gastrointest Endosc (1997) 2.28
Yield of endoscopic ultrasound-guided fine-needle aspiration biopsy in patients with suspected pancreatic carcinoma. Cancer (2003) 2.24
Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness. Cancer Res (2002) 2.21
Molecular prognostic markers in pancreatic cancer: a systematic review. Eur J Cancer (2005) 2.20
Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer. Breast Cancer Res (2002) 2.04
Total RNA yield and microarray gene expression profiles from fine-needle aspiration biopsy and core-needle biopsy samples of breast carcinoma. Cancer (2003) 2.01
Assessment of complications of EUS-guided fine-needle aspiration. Gastrointest Endosc (2001) 1.94
Endoscopic ultrasound-guided fine-needle aspiration biopsy: a powerful tool to obtain samples from small lesions. Cancer (2004) 1.92
Incidence and clinical findings of benign, inflammatory disease in patients resected for presumed pancreatic head cancer. Gastrointest Endosc (1997) 1.88
Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells. Br J Cancer (2007) 1.87
Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers. Clin Cancer Res (2004) 1.74
Allelic loss is often the first hit in the biallelic inactivation of the p53 and DPC4 genes during pancreatic carcinogenesis. Am J Pathol (2001) 1.69
New MUC1 serum immunoassay differentiates pancreatic cancer from pancreatitis. J Clin Oncol (2005) 1.45
Expression of the IAP protein family is dysregulated in pancreatic cancer cells and is important for resistance to chemotherapy. Int J Cancer (2007) 1.44
Endoscopic ultrasound-guided fine-needle aspiration in 179 cases: the M. D. Anderson Cancer Center experience. Cancer (2002) 1.39
Biomarkers in Diagnosis of pancreatic carcinoma in fine-needle aspirates. Am J Clin Pathol (2006) 1.39
CEACAM1, a novel serum biomarker for pancreatic cancer. Pancreas (2007) 1.39
Endoscopic ultrasound-guided fine needle aspiration biopsy: equipment and technique. J Gastroenterol Hepatol (2006) 1.20
Expression of MUC1, MUC2, MUC3 and MUC4 mucin mRNAs in human pancreatic and intestinal tumor cell lines. Int J Cancer (1994) 1.13
In situ hybridization shows distinct patterns of mucin gene expression in normal, benign, and malignant pancreas tissues. Gastroenterology (1995) 1.13
Accurate discrimination of pancreatic ductal adenocarcinoma and chronic pancreatitis using multimarker expression data and samples obtained by minimally invasive fine needle aspiration. Int J Cancer (2007) 1.12
Progress on molecular markers of pancreatic cancer. Curr Opin Gastroenterol (2007) 1.11
CEACAM6 is a determinant of pancreatic adenocarcinoma cellular invasiveness. Br J Cancer (2004) 1.10
Endoscopic ultrasound and fine needle aspiration for the evaluation of pancreatic masses. Arch Surg (1999) 1.09
Identification of biomarkers of human pancreatic adenocarcinomas by expression profiling and validation with gene expression analysis in endoscopic ultrasound-guided fine needle aspiration samples. World J Gastroenterol (2006) 1.09
Detection of disseminated pancreatic cells by amplification of cytokeratin-19 with quantitative RT-PCR in blood, bone marrow and peritoneal lavage of pancreatic carcinoma patients. World J Gastroenterol (2007) 0.94
Feasibility of using low-volume tissue samples for gene expression profiling of advanced non-small cell lung cancers. Clin Cancer Res (2003) 0.94
Survivin expression in pancreatic intraepithelial neoplasia (PanIN): steady increase along the developmental stages of pancreatic ductal adenocarcinoma. Am J Surg Pathol (2006) 0.94
aRNA-longSAGE: a new approach to generate SAGE libraries from microdissected cells. Nucleic Acids Res (2004) 0.91
Clinical utility of quantitative RT-PCR targeted to alpha1,4-N-acetylglucosaminyltransferase mRNA for detection of pancreatic cancer. Cancer Sci (2006) 0.83
Differentiation of chronic pancreatitis from pancreatic cancer: recent advances in molecular diagnosis. Dig Dis (2001) 0.79
RAS is regulated by the let-7 microRNA family. Cell (2005) 30.24
The colorectal microRNAome. Proc Natl Acad Sci U S A (2006) 11.59
Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing. Nat Med (2006) 6.96
Small molecule inhibition of the KRAS-PDEδ interaction impairs oncogenic KRAS signalling. Nature (2013) 5.04
Pathology of genetically engineered mouse models of pancreatic exocrine cancer: consensus report and recommendations. Cancer Res (2006) 4.83
Lyme borreliosis. Lancet Infect Dis (2003) 4.58
Characterization of Foxp3+CD4+CD25+ and IL-10-secreting CD4+CD25+ T cells during cure of colitis. J Immunol (2006) 4.04
Can women with early-stage breast cancer make an informed decision for mastectomy? J Clin Oncol (2008) 3.37
An optimized isolation and labeling platform for accurate microRNA expression profiling. RNA (2005) 3.12
MicroRNAs: novel biomarkers for human cancer. Clin Chem (2009) 2.97
MicroRNA-10b expression correlates with response to neoadjuvant therapy and survival in pancreatic ductal adenocarcinoma. Clin Cancer Res (2011) 2.95
Combined TLR and CD40 triggering induces potent CD8+ T cell expansion with variable dependence on type I IFN. J Exp Med (2004) 2.89
MicroRNA-31 functions as an oncogenic microRNA in mouse and human lung cancer cells by repressing specific tumor suppressors. J Clin Invest (2010) 2.87
Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment. J Clin Oncol (2009) 2.66
Intraductal papillary mucinous neoplasms of the pancreas: an analysis of clinicopathologic features and outcome. Ann Surg (2004) 2.62
Evaluation and validation of total RNA extraction methods for microRNA expression analyses in formalin-fixed, paraffin-embedded tissues. J Mol Diagn (2008) 2.50
Vascular endothelial growth factor-trap suppresses tumorigenicity of multiple pancreatic cancer cell lines. Clin Cancer Res (2004) 2.48
Identification of microRNAs in the cerebrospinal fluid as marker for primary diffuse large B-cell lymphoma of the central nervous system. Blood (2011) 2.44
Pancreatic cancer and precursor pancreatic intraepithelial neoplasia lesions are devoid of primary cilia. Cancer Res (2009) 2.43
Wireless capsule endoscopy for diagnosis of acute intestinal graft-versus-host disease. Gastrointest Endosc (2007) 2.27
Uncovering growth-suppressive MicroRNAs in lung cancer. Clin Cancer Res (2009) 2.19
The Nestin progenitor lineage is the compartment of origin for pancreatic intraepithelial neoplasia. Proc Natl Acad Sci U S A (2007) 2.18
Transcriptome analysis of microdissected pancreatic intraepithelial neoplastic lesions. Oncogene (2005) 2.14
p16, p14, p53, and cyclin D1 expression and HPV analysis in small cell carcinomas of the uterine cervix. Int J Gynecol Pathol (2006) 2.04
Acute pancreatitis markedly accelerates pancreatic cancer progression in mice expressing oncogenic Kras. Biochem Biophys Res Commun (2009) 2.04
Surgical and palliative management and outcome in 184 patients with hilar cholangiocarcinoma: palliative photodynamic therapy plus stenting is comparable to r1/r2 resection. Ann Surg (2006) 2.03
Levels of alanine aminotransferase confound use of transient elastography to diagnose fibrosis in patients with chronic hepatitis C virus infection. Clin Gastroenterol Hepatol (2012) 2.02
MicroRNA-21 is induced early in pancreatic ductal adenocarcinoma precursor lesions. Clin Chem (2010) 1.95
TFAP2E-DKK4 and chemoresistance in colorectal cancer. N Engl J Med (2012) 1.94
Clinical and immunologic effects of intranodal autologous tumor lysate-dendritic cell vaccine with Aldesleukin (Interleukin 2) and IFN-{alpha}2a therapy in metastatic renal cell carcinoma patients. Clin Cancer Res (2009) 1.94
Functional assessment of pancreatic beta-cell area in humans. Diabetes (2009) 1.82
Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential. Oncogene (2005) 1.80
Partial pancreatectomy in adult humans does not provoke beta-cell regeneration. Diabetes (2007) 1.78
Malignant pleural mesothelioma: incidence, etiology, diagnosis, treatment, and occupational health. Dtsch Arztebl Int (2013) 1.72
Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas. Virchows Arch (2011) 1.72
Connective tissue growth factor-specific antibody attenuates tumor growth, metastasis, and angiogenesis in an orthotopic mouse model of pancreatic cancer. Mol Cancer Ther (2006) 1.71
IgG4-related autoimmune diseases: Polymorphous presentation complicates diagnosis and treatment. Dtsch Arztebl Int (2015) 1.70
Inhibition of heme oxygenase 1 expression by small interfering RNA decreases orthotopic tumor growth in livers of mice. Int J Cancer (2008) 1.68
Retracted Inactivation of Ink4a/Arf leads to deregulated expression of miRNAs in K-Ras transgenic mouse model of pancreatic cancer. J Cell Physiol (2012) 1.67
Transgenic cyclin E triggers dysplasia and multiple pulmonary adenocarcinomas. Proc Natl Acad Sci U S A (2007) 1.61
Bexarotene plus erlotinib suppress lung carcinogenesis independent of KRAS mutations in two clinical trials and transgenic models. Cancer Prev Res (Phila) (2011) 1.61
Epigenetic silencing of the PTEN gene in melanoma. Cancer Res (2006) 1.58
Establishment and validation of analytical reference panels for the standardization of quantitative BCR-ABL1 measurements on the international scale. Clin Chem (2013) 1.58
Screening for recurrences in patients treated with breast-conserving surgery: is there a role for MRI? Ann Surg Oncol (2008) 1.56
Pancreatic Expression database: a generic model for the organization, integration and mining of complex cancer datasets. BMC Genomics (2007) 1.56
SOCS-3 is frequently methylated in head and neck squamous cell carcinoma and its precursor lesions and causes growth inhibition. Oncogene (2005) 1.55
Accurate molecular characterization of formalin-fixed, paraffin-embedded tissues by microRNA expression profiling. J Mol Diagn (2008) 1.52
Further exploration of the relationship between insulin glargine and incident cancer: a retrospective cohort study of older Medicare patients. Diabetes Care (2011) 1.52
Reprogramming tumor-associated dendritic cells in vivo using miRNA mimetics triggers protective immunity against ovarian cancer. Cancer Res (2012) 1.51
Growth factor-induced shedding of syndecan-1 confers glypican-1 dependence on mitogenic responses of cancer cells. J Cell Biol (2005) 1.51
Norepinephrine-induced changes in cardiac transforming growth factor-beta isoform expression pattern of female and male rats. Hypertension (2004) 1.50
Global microRNA expression profiling of microdissected tissues identifies miR-135b as a novel biomarker for pancreatic ductal adenocarcinoma. Int J Cancer (2011) 1.47
Total body weight loss of ≥ 10 % is associated with improved hepatic fibrosis in patients with nonalcoholic steatohepatitis. Dig Dis Sci (2014) 1.45
Fluorescence-based codetection with protein markers reveals distinct cellular compartments for altered MicroRNA expression in solid tumors. Clin Cancer Res (2010) 1.44
ECRG4 is a candidate tumor suppressor gene frequently hypermethylated in colorectal carcinoma and glioma. BMC Cancer (2009) 1.44
Membrane-associated heparan sulfate proteoglycans are involved in the recognition of cellular targets by NKp30 and NKp46. J Immunol (2004) 1.43
Enhanced efficacy and reduced toxicity of multifactorial adjuvants compared with unitary adjuvants as cancer vaccines. Blood (2008) 1.43
Glypican-1 modulates the angiogenic and metastatic potential of human and mouse cancer cells. J Clin Invest (2008) 1.43
International standards and reference materials for quantitative molecular infectious disease testing. J Mol Diagn (2010) 1.39
MiR-30a-5p suppresses tumor growth in colon carcinoma by targeting DTL. Carcinogenesis (2012) 1.39
The silencing of microRNA 148a production by DNA hypermethylation is an early event in pancreatic carcinogenesis. Clin Chem (2010) 1.37
[18F]Fluoroazomycinarabinofuranoside (18FAZA) and [18F]Fluoromisonidazole (18FMISO): a comparative study of their selective uptake in hypoxic cells and PET imaging in experimental rat tumors. Nucl Med Biol (2003) 1.36
Intraductal papillary mucinous adenoma that arises from pancreatic heterotopia within a meckel diverticulum. Arch Pathol Lab Med (2005) 1.35
Comparative microarray analysis of microRNA expression profiles in primary cutaneous malignant melanoma, cutaneous malignant melanoma metastases, and benign melanocytic nevi. Cell Tissue Res (2012) 1.35
Neoadjuvant photodynamic therapy as a new approach to treating hilar cholangiocarcinoma: a phase II pilot study. Cancer (2003) 1.35
Routine use of the Ion Torrent AmpliSeq™ Cancer Hotspot Panel for identification of clinically actionable somatic mutations. Clin Chem Lab Med (2014) 1.34
Absence of mutations of the BRAF gene and constitutive activation of extracellular-regulated kinase in malignant melanomas of the uvea. Lab Invest (2003) 1.33
Determination of temperature elevation in tissue during the application of the harmonic scalpel. Ultrasound Med Biol (2003) 1.32
HNPCC-associated small bowel cancer: clinical and molecular characteristics. Gastroenterology (2005) 1.32
Mutations of the BRAF gene in squamous cell carcinoma of the head and neck. Oncogene (2003) 1.32
SMIF, a Smad4-interacting protein that functions as a co-activator in TGFbeta signalling. Nat Cell Biol (2002) 1.31
Docetaxel/Gemcitabine followed by gemcitabine and external beam radiotherapy in patients with pancreatic adenocarcinoma. Ann Surg Oncol (2005) 1.30
MicroRNA-148a is down-regulated in human pancreatic ductal adenocarcinomas and regulates cell survival by targeting CDC25B. Lab Invest (2011) 1.30
Isolated asymptomatic ileitis does not progress to overt Crohn disease on long-term follow-up despite features of chronicity in ileal biopsies. Am J Surg Pathol (2009) 1.29
Neuropilin-1 interacts with integrin beta1 and modulates pancreatic cancer cell growth, survival and invasion. Cancer Biol Ther (2007) 1.28
The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances gemcitabine-induced cell death in pancreatic cancer. Clin Cancer Res (2007) 1.27
Hepatocyte growth factor-mediated cell invasion in pancreatic cancer cells is dependent on neuropilin-1. Cancer Res (2007) 1.26
The additive blood pressure lowering effects of exercise intensity on post-exercise hypotension. Am Heart J (2010) 1.24
Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patients. Cancer Treat Rev (2013) 1.23
In vivo quantitative imaging of normal and cancerous breast tissue using broadband diffuse optical tomography. Med Phys (2010) 1.23
The correlation of in vivo and ex vivo tissue dielectric properties to validate electromagnetic breast imaging: initial clinical experience. Physiol Meas (2009) 1.22
Loss of beta-catenin expression in metastatic gastric cancer. J Clin Oncol (2003) 1.22
Genome-wide analysis reveals an unexpected function for the Drosophila splicing factor U2AF50 in the nuclear export of intronless mRNAs. Mol Cell (2004) 1.21
Identification and expression analysis of the aldo-ketoreductase1-B10 gene in primary malignant liver tumours. J Hepatol (2009) 1.21
Brain metastases from colorectal cancer: risk factors, incidence, and the possible role of chemokines. Clin Colorectal Cancer (2009) 1.20
Adhesion molecules in human pancreatic cancer. J Surg Oncol (2002) 1.19
Reverse transcription-PCR analysis of laser-captured cells points to potential paracrine and autocrine actions of neurotrophins in pancreatic cancer. Clin Cancer Res (2003) 1.19
Characterization of "Candidatus piscichlamydia salmonis" (order Chlamydiales), a chlamydia-like bacterium associated with epitheliocystis in farmed Atlantic salmon (Salmo salar). J Clin Microbiol (2004) 1.19
CDKN2A germline mutations in familial pancreatic cancer. Ann Surg (2002) 1.18
Circulating U2 small nuclear RNA fragments as a novel diagnostic biomarker for pancreatic and colorectal adenocarcinoma. Int J Cancer (2012) 1.18